Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Forget the share price ... follow the bouncing H2S molecule

<< Previous

Bullboard Posts

Next >>

Comment by AntibeTribeon Apr 23, 2021 8:35am

104 Views

Post# 33053949

RE:Forget the share price ... follow the bouncing H2S molecule

very interesting turn of events to your GUD point, Mugs.
MONTREAL, April 23, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement under which Knight will acquire the exclusive rights to manufacture, market and sell Exelon (rivastigmine Patch, Capsules and Solution) in Canada and Latin America (the Territory), as well as an exclusive license to use the intellectual property and the Exelon trademark, from Novartis within the Territory.

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload